AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Abbvie (ABBV) PT Raised to $212 at Goldman Sachs
February 3, 2025 5:17 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $212.00 (from $208.00) while maintaining a Buy rating.
The analyst comments "Relative outperformance from ABBV shares (+4.7% on Friday vs. XLV -0.3%) was earned in our view, with continued strong momentum from Skyrizi and Rinvoq enabling the delivery of... More
AbbVie (ABBV) Tops Q4 EPS by 10c, Offers Guidance
January 31, 2025 7:37 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $2.16, $0.10 better than the analyst estimate of $2.06. Revenue for the quarter came in at $15.1 billion versus the consensus estimate of $14.82 billion.
GUIDANCE:
AbbVie sees FY2025 EPS of $12.12-$12.32, versus the consensus of $12.13.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More